-
1
-
2
-
3
-
4
-
5
-
6
1050 Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non mu...
Veröffentlicht in European urology supplements : official journal of the European Association of Urology
VolltextArtikel -
7
659 EFFECT OF AGE ON TREATMENT OUTCOME AND TOLERANCE IN PATIENTS WITH STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE BACILLUS CALMETTEGUERIN: RESULTS OF EO...
Veröffentlicht in European urology supplements : official journal of the European Association of Urology
VolltextArtikel -
8
PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-G...
Veröffentlicht in European urology supplements : official journal of the European Association of Urology
VolltextArtikel -
9
-
10
-
11
-
12
LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTEGUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STA...
Veröffentlicht in European urology supplements : official journal of the European Association of Urology
VolltextArtikel -
13
-
14
-
15
Guidelines for diagnosis, treatment, and follow-up of bladder cancer
Veröffentlicht in Urologic oncology
VolltextArtikel